Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022
January 06 2022 - 8:00AM
Business Wire
Pivotal trial of BT-001 in type 2 diabetes
fully enrolled; interim data analysis determines trial is
adequately powered and should continue to completion without
changes; primary endpoint readout expected in Q1 2022
Early clinical discovery study in nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
expected to commence enrollment in Q1 2022
Mass General Brigham (MGB) joins Colorado
Prevention Center (CPC) and Catalyst Health Network (Catalyst) in
real-world evidence initiative evaluating the long-term
effectiveness and healthcare cost impact of BT-001 expected to
commence enrollment in Q1 2022
Recent additions to the leadership team include
Chief People and Chief Strategy Officers, and Senior Vice President
of Clinical Development
Chardan, Cowen and Company, Lake Street Capital
Markets and LifeSci Capital have initiated coverage of BTTX since
its public debut on NASDAQ
Better Therapeutics, Inc. (“Better
Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics
(PDT) company developing cognitive behavioral therapy to address
root causes of cardiometabolic diseases, today provided an update
on recent progress.
“We’ve made excellent progress since
debuting as a public company,” said Kevin Appelbaum, co-founder and
chief executive officer of Better Therapeutics. “Our clinical
development pipeline across multiple product candidates is
progressing as planned. Our potentially pivotal study of BT-001, a
PDT for treating type 2 diabetes, is now fully enrolled and primary
endpoint data is expected later this quarter. Mass General Brigham
has joined our research effort to evaluate the long-term
effectiveness and impact on health care utilization and medication
use in real-world clinical practice alongside CPC and Catalyst, and
all three sites will be enrolling patients this quarter. We
strengthened our team with key additions across all functions. We
also recognize we are in the very early stages of creating a new
modality for treating diseases caused by behaviors using regulated
and prescribed software instead of molecules, and are pleased to
have multiple analysts doing independent research on our company in
order to educate investors about the PDT opportunity in general,
and Better Therapeutics in particular.”
The Better Therapeutics platform
blends clinical, behavioral and psychological inputs into a series
of cognitive behavioral therapy lessons and skill-building modules
designed to shift neural pathways of the brain and treat the
disease at its source through behavior change. If the FDA provides
marketing authorization, it is anticipated that primary care
providers will prescribe, and insurers will reimburse, Better
Therapeutics’ PDTs much like they would a traditional
medication.
Clinical data on the efficacy and safety of Better Therapeutics
developmental product candidates has been published in multiple
peer-review journals including Journal of the Endocrine Society,
JMIR Cardio, JMIR Diabetes and more.
About Better Therapeutics
Better Therapeutics is a
prescription digital therapeutics (PDT) company developing a novel
form of cognitive behavioral therapy to address the root causes of
cardiometabolic diseases. The company has developed a proprietary
platform for the development of FDA-regulated, software-based
solutions for type 2 diabetes, heart disease and other conditions.
The cognitive behavioral therapy delivered by Better Therapeutics’
PDT is designed to enable changes in neural pathways of the brain
so lasting changes in behavior become possible. Addressing the
underlying causes of these diseases has the potential to
dramatically improve patient health while lowering healthcare
costs. Better Therapeutics clinically validated mobile applications
are intended to be prescribed by physicians and reimbursed like
traditional medicines. For more information visit: bettertx.com
Forward-Looking
Statements
Certain statements made in this
press release are "forward-looking statements" within the meaning
of the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are typically identified by words such as “plan,”
“believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,”
“forecast,” “project,” “continue,” “could,” “may,” “might,”
“possible,” “potential,” “predict,” “should,” “would” and other
similar words and expressions, but the absence of these words does
not mean that a statement is not forward-looking. The
forward-looking statements are based on the current expectations of
the management of Better Therapeutics and are inherently subject to
uncertainties and changes in circumstances and their potential
effects and speak only as of the date of such statement. There can
be no assurance that future developments will be those that have
been anticipated. These forward-looking statements involve a number
of risks, uncertainties or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements including:
risks related to Better Therapeutics’ business, such as the
willingness of the FDA to approve PDTs and insurance companies to
reimburse their use; and other risks and uncertainties included
under the header “Risk Factors” in the definitive proxy
statement/prospectus filed by us on October 12, 2021.
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005199/en/
Heidi Chokeir, Ph.D. heidi.chokeir@canalecomm.com +1 619 203
5391
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Sep 2023 to Sep 2024